IMMUCELL CORP /DE/
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $27.6M | $26.5M | $17.5M | $18.6M | $19.2M |
| Cost of revenue | $16.2M | $18.6M | $13.6M | $10.9M | $10.6M |
| Gross profit | $11.4M | $7.9M | $3.9M | $7.6M | $8.7M |
| Research and development | $3.0M | $3.9M | $4.4M | $4.5M | $4.2M |
| Operating expenses | $9.8M | $9.6M | $9.6M | $9.9M | $8.4M |
| Operating income | $1.6M | -$1.6M | -$5.7M | -$2.3M | $257,385 |
| Interest expense | $493,384 | $568,725 | $475,598 | $348,536 | $314,359 |
| Pretax income | -$1.0M | -$2.1M | -$5.8M | -$2.5M | -$69,127 |
| Income tax expense | $11,570 | $10,056 | $4,627 | $7,672 | $9,165 |
| Net income | -$1.0M | -$2.2M | -$5.8M | -$2.5M | -$78,292 |
| Balance Sheet | |||||
| Cash and equivalents | $3.8M | $3.8M | $978,741 | $5.8M | $10.2M |
| Current assets | $16.9M | $15.0M | $11.5M | $14.0M | $16.3M |
| Total assets | $42.5M | $45.1M | $43.8M | $44.9M | $44.5M |
| Current liabilities | $4.0M | $4.4M | $4.2M | $3.1M | $2.5M |
| Total liabilities | $15.5M | $17.6M | $18.8M | $14.5M | $11.9M |
| Total debt | — | $10.5M | $12.0M | — | — |
| Stockholders' equity | $27.1M | $27.5M | $25.0M | $30.4M | $32.6M |
| Cash Flow Statement | |||||
| Cash from operations | $2.5M | $357,903 | -$4.7M | -$1.5M | $954,170 |
| Depreciation and amortization | $2.8M | $2.7M | $2.7M | $2.5M | $2.4M |
| Stock-based compensation | $295,871 | $325,551 | $368,866 | $266,244 | $144,313 |
| Capital expenditure | $1.3M | $465,725 | $1.9M | $4.0M | $2.6M |
| Free cash flow | $1.2M | -$107,822 | -$6.6M | -$5.5M | -$1.7M |
| Impairments | $2.7M | $0 | — | — | — |
Shares outstanding 9.0M · Free float 68.7%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.